I had the pleasure of attending the 4th Annual pharmacovigilance conference in Dubai on the 15th January. It was a very interesting conference that certainly opened my eyes to
28 Jan, 2015
The objective of a drug treatment is to deliver specific benefits to the patient. However, no drug is devoid of risk. Effective risk management ensures that expected benefits
Dr Seema Jaitly, founder at Essjay Solutions, will be presenting and facilitating a workshop at the ‘Back to Basics in Pharmacovigilance’ course held by the Drug Safety
15 Jan, 2015
By Dr. Seema Jaitly, Essjay Solutions With the advent of the new PV legislation within the EU, there is an increasing need to focus on documented benefit:risk of medicinal
Essjay Solutions are pleased to announce they will be presenting at the 4th Annual Pharmacovigilance Conference organised by MCO on 15th January 2015 in Dubai. This conference
Finalised safety procedure for methadone products containing povidone. The PRAC finalised the EU safety referral procedure for methadone medicinal products containing
05 Dec, 2013
Watch this space for all our news updates.
Recent Posts
- EU QPPV/UK QPPV and local requirements: is this now a global role?
- Essjay Newsletter – October 2019
- Are your UK PV operations Brexit ready?
- New Approvals and Launches June
- Submitting Risk Management Plans on the New EU template: 3 tips
- How to Manage Compliant Reference Safety Information (RSI) and maintain compliance